Molebogeng X Rangaka

List of Publications by Year
in descending order

51 papers	3,114 citations	304743 22 h-index	265206 42 g-index
51 all docs	51 docs citations	51 times ranked	4008 citing authors

#	ARTICLE	IF	CITATIONS
1	Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clinical Microbiology Reviews, 2014, 27, 3-20.	13.6	662
2	Predictive value of interferon-Î³ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2012, 12, 45-55.	9.1	441
3	Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet, The, 2014, 384, 682-690.	13.7	229
4	Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19013-19017.	7.1	174
5	The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges. Journal of Infectious Diseases, 2017, 216, S702-S713.	4.0	170
6	Neurologic Manifestations of Paradoxical Tuberculosisâ€Associated Immune Reconstitution Inflammatory Syndrome: A Case Series. Clinical Infectious Diseases, 2009, 48, e96-e107.	5.8	163
7	Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet, The, 2015, 386, 2344-2353.	13.7	156
8	Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. Lancet Respiratory Medicine,the, 2020, 8, 395-406.	10.7	128
9	A user-centred design framework for mHealth. PLoS ONE, 2020, 15, e0237910.	2.5	95
10	Novel Relationship between Tuberculosis Immune Reconstitution Inflammatory Syndrome and Antitubercular Drug Resistance. Clinical Infectious Diseases, 2009, 48, 667-676.	5.8	93
11	Clinical, Immunological, and Epidemiological Importance of Antituberculosis T Cell Responses in HIV-Infected Africans. Clinical Infectious Diseases, 2007, 44, 1639-1646.	5.8	79
12	Corticosteroid-modulated Immune Activation in the Tuberculosis Immune Reconstitution Inflammatory Syndrome. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 369-377.	5.6	75
13	Dissection of Regenerating T-Cell Responses against Tuberculosis in HIV-infected Adults Sensitized byMycobacterium tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 674-683.	5.6	60
14	Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nature Medicine, 2020, 26, 1941-1949.	30.7	58
15	QuantiFERON-TB Gold: state of the art for the diagnosis of tuberculosis infection?. Expert Review of Molecular Diagnostics, 2006, 6, 663-677.	3.1	51
16	Effect of Antiretroviral Therapy on the Diagnostic Accuracy of Symptom Screening for Intensified Tuberculosis Case Finding in a South African HIV Clinic. Clinical Infectious Diseases, 2012, 55, 1698-1706.	5.8	48
17	Pneumocystis jirovecii Pneumonia in Tropical and Low and Middle Income Countries: A Systematic Review and Meta-Regression. PLoS ONE, 2013, 8, e69969.	2.5	44
18	Tests for tuberculosis infection: landscape analysis. European Respiratory Journal, 2021, 58, 2100167.	6.7	35

#	Article	IF	Citations
19	Cytotoxic Mediators in Paradoxical HIV–Tuberculosis Immune Reconstitution Inflammatory Syndrome. Journal of Immunology, 2015, 194, 1748-1754.	0.8	31
20	Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV,the, 2021, 8, e8-e15.	4.7	31
21	The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-Î³ release assays: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2022, 22, 250-264.	9.1	31
22	Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. Lancet Infectious Diseases, The, 2022, 22, 507-518.	9.1	28
23	Plasmacytoid Dendritic Cells Infiltrate the Skin in Positive Tuberculin Skin Test Indurations. Journal of Investigative Dermatology, 2012, 132, 114-123.	0.7	24
24	Population tailored modification of tuberculosis specific interferon-gamma release assay. Journal of Infection, 2016, 72, 179-188.	3.3	23
25	Optimizing Tuberculosis Diagnosis in Human Immunodeficiency Virus–Infected Inpatients Meeting the Criteria of Seriously Ill in the World Health Organization Algorithm. Clinical Infectious Diseases, 2018, 66, 1419-1426.	5.8	21
26	What can 5G do for healthcare in Africa?. Nature Electronics, 2020, 3, 7-9.	26.0	19
27	Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. Aids, 2016, 30, 1279-1286.	2.2	17
28	Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis. Lancet HIV,the, 2022, 9, e233-e241.	4.7	15
29	Enhanced Ex Vivo Stimulation of Mycobacterium tuberculosis -Specific T Cells in Human Immunodeficiency Virus-Infected Persons via Antigen Delivery by the Bordetella pertussis Adenylate Cyclase Vector. Vaccine Journal, 2007, 14, 847-854.	3.1	14
30	Update in Tuberculosis and Nontuberculous Mycobacteria 2017. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1248-1253.	5.6	14
31	Mobile phone-based evaluation of latent tuberculosis infection: Proof of concept for an integrated image capture and analysis system. Computers in Biology and Medicine, 2018, 98, 76-84.	7.0	14
32	Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus–1. Clinical Infectious Diseases, 2019, 69, 295-305.	5.8	10
33	Measurement of Skin Induration Size Using Smartphone Images and Photogrammetric Reconstruction: Pilot Study. JMIR Biomedical Engineering, 2017, 2, e3.	1.2	10
34	Tuberculosis Antigen-Specific T-Cell Responses During the First 6 Months of Antiretroviral Treatment. Journal of Infectious Diseases, 2020, 221, 162-167.	4.0	9
35	Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. Aids, 2019, 33, 525-536.	2.2	7
36	Latent tuberculosis infection screening and treatment in congregate settings (TB FREE COREA): protocol for a prospective observational study in Korea. BMJ Open, 2020, 10, e034098.	1.9	7

#	Article	IF	Citations
37	C-Tb: a latent tuberculosis skin test for the 21st century?. Lancet Respiratory Medicine,the, 2017, 5, 236-237.	10.7	6
38	Development of a clinical prediction rule to diagnose Pneumocystis jirovecii pneumonia in the World Health Organization's algorithm for seriously ill HIV-infected patients. Southern African Journal of HIV Medicine, 2018, 19, 851.	0.9	6
39	Eliminating tuberculosis in low-burden countries. International Journal of Tuberculosis and Lung Disease, 2018, 22, 3-3.	1.2	5
40	Diagnostic accuracy of WHO screening criteria to guide lateral-flow lipoarabinomannan testing among HIV-positive inpatients: A systematic review and individual participant data meta-analysis. Journal of Infection, 2022, 85, 40-48.	3.3	5
41	Evaluating patient education resources for supporting treatment decisions in latent tuberculosis infection. Health Education Journal, 2021, 80, 513-528.	1.2	3
42	Ending the tuberculosis syndemic: is COVID-19 the (in)convenient scapegoat for poor progress?. Lancet Respiratory Medicine,the, 2022, 10, 529-531.	10.7	3
43	Improving the predictive value of interferon-gamma release assays: do our methods go far enough? [Editorial]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1516-1516.	1.2	0
44	The Risk of Falsely Declaring Noninferiority of Novel Latent Tuberculosis Treatment in Large Trials. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 511-513.	5.6	0
45	Randomised controlled trial to evaluate the effectiveness of using the RD-1-based C-Tb skin test as a replacement for blood-based interferon-γ release assay for detection of, and initiation of preventive treatment for, tuberculosis infection: RID-TB:Dx study protocol. BMJ Open, 2021, 11, e050595.	1.9	0
46	A user-centred design framework for mHealth. , 2020, 15, e0237910.		0
47	A user-centred design framework for mHealth. , 2020, 15, e0237910.		0
48	A user-centred design framework for mHealth. , 2020, 15, e0237910.		0
49	A user-centred design framework for mHealth. , 2020, 15, e0237910.		0
50	A user-centred design framework for mHealth. , 2020, 15, e0237910.		0
51	A user-centred design framework for mHealth. , 2020, 15, e0237910.		0